For Healthcare Professionals
A new approach
to enteral feeding access.
The Alsteni System is an investigational intraoral feeding platform currently in development. Published feasibility data demonstrated zero serious adverse events across 334 tube-days (Beale et al., Nutrition & Diabetes, 2020).
We are actively building clinical partnerships for our upcoming FDA-required study. If you are interested in learning more about the technology or exploring clinical collaboration, please contact our clinical team.
Scientific Advisory Board
Guided by leaders
in the field.
Our Scientific Advisory Board includes researchers and clinicians from institutions that define the standard of care in enteral nutrition, gut hormone physiology, and device-based therapy.
Prof. Michael Horowitz, AO
University of Adelaide
H-index 132. Golgi Prize recipient. One of the world’s foremost researchers in gut hormone physiology and gastric motility. Co-author with Dr. Beale on the hypothesis paper establishing the scientific rationale for bolus enteral nutrient delivery.
Dr. Hongsheng Tong
USC / InBrace
Raised $173–$219M in venture funding. 10,000+ patients treated. Intraoral device expert whose work directly informs the Alsteni Anchor design. Deep expertise in intraoral device engineering and commercial scale-up.
Dr. Manpreet Mundi
Mayo Clinic
Director, Home Enteral Nutrition Program. ASPEN Dudrick Research Scholar Award recipient. National authority on enteral nutrition practice, outcomes research, and malnutrition management.
Dr. David Seres
Columbia University
ASPEN Board member. UpToDate editor for nutrition topics. Abbott nutrition advisor. Leading voice in evidence-based nutrition support and clinical nutrition policy.
Dr. Demetrios Demetriades
USC Keck School of Medicine
Director, Trauma Surgery. Extensive research in critical care nutrition and trauma patient outcomes. LAC+USC Medical Center.
Dr. John Anwar
Academic Medical Center
Academic lead for the FDA-required clinical study. Faculty champion providing IRB infrastructure and clinical oversight for the next phase of Alsteni’s evidence generation.